Abstract: A crystalline form A of 2,2-bis(4-fluorophenyl)-2-phenylacetamide is provided. The crystalline form has good light stability, high temperature stability, and high humidity stability.

Abstract: Disclosed are eutectic form A of Elagolix and pyrimethamine, a preparation method therefor and a use thereof. Using Cu-K? radiation, eutectic form A has characteristic peaks represented by a 2? degree at 8.1±0.2°, 12.2±0.2°, 13.3±0.2° and 21.1±0.2° in an X-ray powder diffraction. Eutectic form A has a high purity, a good light radiation stability, a high temperature stability, a high humidity stability and an accelerated stability, is easy to store, and has a slow moisture absorption under the condition of relatively low humidity, wherein the weight gain of eutectic form A by moisture absorption is not more than 1.08% when the relative humidity increases from 0 to 60% RH. Production conditions for eutectic form A are easy to control, same has a simple preparation process and a stable quality, and is easy to industrially produce on a large-scale.

Abstract: Provided is crystal form A of N,N?-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16, 18-tetrazohexahexane-1,26-di-yl)bis(4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline-4-yl) benzene sulfonamide. The crystal form has good light stability, high-temperature stability, and high-humidity stability.

Abstract: A crystal form X of 3?-hydroxy-3?-methyl-21-(4-cyano-1H-pyrazol-1?-yl)-19-nor-5?-pregnan-20-one, a preparation method of said crystal form and an application thereof in preparing a drug for treatment of central nervous system disease.

Abstract: Provided are a pyrroloquinoline quinone glycine betaine salt and a crystalline form thereof. The pyrroloquinoline quinone glycine betaine salt has the advantages of high solubility, good stability, a simple preparation process and low solvent residue.

Abstract: Disclosed is crystal form M of the proline hydroxylase inhibitor daprodustat, wherein the X-ray powder diffraction thereof, expressed in 2? angles and using Cu-Ka radiation, has characteristic peaks at 4.7±0.2°, 6.5±0.2°, and 6.8±0.2°. Disclosed are the preparation method for and the use of crystal form M. The crystal form M has good light stability, high temperature stability and high humidity stability, good solubility, and high purity.

Abstract: Provided are a crystal form of a gonadotropin releasing hormone antagonist, a preparation method therefor, and use thereof. A crystal form C and a crystal form D have high purity, good illumination stability, high temperature stability, and high humidity stability, and have good solubility and low hygroscopicity; the saturation solubility of the crystal form C and the crystal form D is 101.75 ?g/ml and 87.21 ?g/ml, respectively; when the relative humidity is increased from 0 to 50% RH, the hygroscopy gain of the crystal form C and the crystal form D is not greater than 1.76% and 0.73%, respectively; and when the relative humidity is increased from 0 to 90% RH, the hygroscopy gain of the crystal form C and the crystal form D is not greater than 3.43% and 1.61%, respectively. Therefore, the control of a production condition is facilitated, the preparation process is simple, the quality is stable, and large-scale industrial production is easy.

Abstract: Disclosed are eutectic form A of Elagolix and pyrimethamine, a preparation method therefor and a use thereof. Using Cu-K? radiation, eutectic form A has characteristic peaks represented by a 20 degree at 8.1±0.2°, 12.2±0.2°, 13.3±0.2° and 21.1±0.2° in an X-ray powder diffraction. Eutectic form A has a high purity, a good light radiation stability, a high temperature stability, a high humidity stability and an accelerated stability, is easy to store, and has a slow moisture absorption under the condition of relatively low humidity, wherein the weight gain of eutectic form A by moisture absorption is not more than 1.08% when the relative humidity increases from 0 to 60% RH. Production conditions for eutectic form A are easy to control, same has a simple preparation process and a stable quality, and is easy to industrially produce on a large-scale.

Abstract: A crystal form X of 3?-hydroxy-3?-methyl-21-(4-cyano-1H-pyrazol-1?-yl)-19-nor-5?-pregnan-20-one, a preparation method of said crystal form and an application thereof in preparing a drug for treatment of central nervous system disease.

Abstract: A crystalline form A of 2,2-bis(4-fluorophenyl)-2-phenylacetamide is provided. The crystalline form has good light stability, high temperature stability, and high humidity stability.

Abstract: A crystal form A of 2-(2, 5-dioxopyrrolidin-1yl)ethyl methyl fumarate has a good light irradiation stability, high-temperature stability and high-humidity stability.

Abstract: Provided is crystal form A of N, N?-(10, 17-dioxo-3, 6, 21, 24-tetraoxa-9, 11, 16, 18-tetrazohexahexane-1, 26-di-yl)bis(4-(6, 8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline-4-yl) benzene sulfonamide. The crystal form has good light stability, high-temperature stability, and high-humidity stability.

Abstract: A tebuconazole polymorph and a preparation method therefor are described. In particular, a polymorph of (RS)-1-(4-chloropheny)-4,4-dimethyl-3-(1H-1,2,4-triazol-1-ylmethyl) pentan-3-ol, a preparation method therefor and use thereof are provided. The tebuconazole polymorph has a high purity and excellent crystallization properties, is stable under high humidity, high temperature and light conditions, has excellent solubility, and has high processing properties for formulations, high biological activities and good sterilization effects. The preparation method is simple, has stable processes, and can be implemented on a large scale. The polymorph can greatly improve the quality control and industrial application of tebuconazole-containing pesticides.

Abstract: Forms B and C of (R)—N-(4-chlorophenyl)-2-(cis-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide are stable under the conditions of light, high temperature and high humidity.

Abstract: A tebuconazole polymorph and a preparation method therefor are described. In particular, a polymorph of (RS)-1-(4-chloropheny)-4,4-dimethyl-3-(1H-1,2,4-triazol-1-ylmethyl) pentan-3-ol, a preparation method therefor and use thereof are provided. The tebuconazole polymorph has a high purity and excellent crystallization properties, is stable under high humidity, high temperature and light conditions, has excellent solubility, and has high processing properties for formulations, high biological activities and good sterilization effects. The preparation method is simple, has stable processes, and can be implemented on a large scale. The polymorph can greatly improve the quality control and industrial application of tebuconazole-containing pesticides.

Abstract: Provided are a pyrroloquinoline quinone glycine betaine salt and a crystalline form thereof. The pyrroloquinoline quinone glycine betaine salt has the advantages of high solubility, good stability, a simple preparation process and low solvent residue.

Abstract: Forms B and C of (R)—N-(4-chlorophenyl)-2-(cis-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide are stable under the conditions of light, high temperature and high humidity.

Abstract: Provided are several types of ginsenoside polymorphic substances and a method for preparing same. In particular, new crystal form A, crystal form B, crystal form C, crystal form E, crystal form F, crystal form I, crystal form K, crystal form L, crystal form M, crystal form N, and crystal form O are involved.

Abstract: Provided are ginsenoside C-K polymorphic forms and a method for preparing same. The ginsenoside C-K polymorphic forms are crystal form D and crystal form H.

Abstract: Provided are several types of ginsenoside polymorphic substances and a method for preparing same. In particular, new crystal form A, crystal form B, crystal form C, crystal form E, crystal form F, crystal form I, crystal form K, crystal form L, crystal form M, crystal form N, and crystal form O are involved.